查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
2149700

細胞和基因治療市場預測至2034年－全球分析（按生產服務、治療類型、載體類型、生產階段、生產流程、最終用戶和地區分類）

Cell & Gene Therapy Manufacturing Market Forecasts to 2034 - Global Analysis By Manufacturing Service, Therapy Type, Vector Type, Manufacturing Stage, Manufacturing Workflow, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，預計到 2026 年，全球細胞和基因治療製造市場規模將達到 60 億美元，並在預測期內以 15.1% 的複合年成長率成長，到 2034 年將達到 185 億美元。

細胞和基因療法的生產是指專門用於生產活細胞和遺傳物質以達到治療目的的工藝和設施。這些系統透過在嚴格的監管條件下分離、改造和培養患者或供體細胞來確保安全性、有效性和一致性。這些系統包括病毒載體生產、細胞培養和純化技術，從而能夠大規模地生產先進療法。它們的應用確保了針對遺傳性疾病、癌症和罕見疾病的可靠根治性治療，並支持再生醫學領域的擴展。

遺傳性疾病盛行率增加

全球遺傳性疾病和罕見病患疾病的激增迫使製藥公司開發用於細胞和基因療法的生產平台，以提供根治性治療方案。人們日益認知到單劑量療法的長期益處，這正在加速將這些先進的生產流程整合到臨床開發框架中。病毒載體生產技術的進步提高了治療藥物的產量，從而推動了這一轉變。因此，生技公司正在投資專門的生產技術，以在滿足療效標準的同時最佳化生產成本。

複雜的監管和品管要求

活細胞療法的生產涉及極其複雜的監管要求，這嚴重阻礙了其商業性化應用。開發穩定安全的生產流程通常需要複雜的品管技術和先進的監控系統，從而增加了整體生產成本。此外，病患來源的原料的差異性也限制了標準化生產流程的運作可靠性。這些因素共同阻礙了市場擴張，尤其對於監管經驗有限的中小型企業而言更是如此。

擴大異體現成療法的應用

由於對可規模化供體來源療法的需求日益成長，異體療法領域為細胞和基因療法生產商帶來了巨大的成長機會。先進的生產平台能夠有效率地生產標準化治療批次，以成熟的細胞培養技術為主要原料，而無需依賴患者特異性細胞。隨著全球對再生醫學投資的不斷增加，先進的異體療法生產解決方案的應用預計將顯著成長。

與小分子藥物的競爭

對傳統小分子藥物研發的持續依賴對細胞和基因治療藥物生產市場構成重大威脅。在目前的醫療預算下，傳統的化學合成和成熟的藥物生產方法通常具有更高的成本效益，有望為治療慢性疾病提供更經濟可行的選擇。此外，靶向蛋白分解技術的快速發展正在提高傳統療法的療效。這些競爭可能會阻礙市場滲透。

新型冠狀病毒（COVID-19）的影響：

疫情初期，由於設施關閉，供應鏈中斷，臨床試驗也因此延誤。然而，隨後對快速研發疫苗的需求加速了先進病毒載體生產平台在治療藥物生產上的應用。疫情後，人們對生物防禦和再生醫學的關注，加強了對細胞和基因治療生產技術的長期投資，推動了全球各製藥領域的強勁市場復甦和擴張。

在預測期內，細胞療法製造領域預計將佔據最大的市場佔有率。

由於細胞療法生產在治療領域的基礎性作用及其在各種治療環境中的廣泛適用性，預計在預測期內，細胞療法生產領域將佔據最大的市場佔有率。細胞療法生產平台具有卓越的生產擴充性，能夠有效擴增患者來源的細胞。這顯著減少了治療延誤，並最大限度地降低了常規生產過程中的細胞污染。隨著業界對高效且經濟的再生醫學方法的日益重視，對專業細胞療法生產的需求持續激增，鞏固了其在市場上的主導地位。

預計在預測期內，基因編輯細胞療法領域將呈現最高的複合年成長率。

在預測期內，基因編輯細胞療法領域預計將呈現最高的成長速度，這主要得益於CRISPR技術和細胞工程的快速發展。這些技術能夠精確地修改基因序列，從而產生高度專業且穩健的治療效果，並可針對特定疾病進行客製化。透過整合先進的基因編輯技術，提高編輯效率、營運擴充性和治療安全性，將顯著提升製程經濟性，並加速其在全球的商業性化應用。

市佔率最大的地區：

在預測期內，北美預計將佔據最大的市場佔有率，這得益於其成熟的生物技術產業和先進的製造基礎設施，這些基礎設施被廣泛應用於細胞和基因療法的生產。該地區受益於大量的研發投入、健全的智慧財產權保護以及政府對醫療保健領域技術創新的支持。此外，美國和加拿大主要產業參與者對先進製造平台的早期採用，進一步鞏固了該地區的全球主導地位。

複合年成長率最高的地區：

在預測期內，亞太地區預計將呈現最高的複合年成長率，這主要得益於新興經濟體生物技術的快速現代化以及再生醫學領域的擴張。中國、印度和日本等國家正加大對生產基礎設施和細胞治療技術的投資，以滿足日益成長的國內醫療保健需求和日益嚴格的效率監管要求。此外，有利的政府政策、不斷成長的外國直接投資以及經濟高效的技術資源的可用性，正在加速全部區域細胞和基因療法的生產和應用。

免費客製化服務：

所有購買此報告的客戶均可享受以下免費自訂選項之一：

  • 企業概況
    • 對其他市場參與者（最多 3 家公司）進行全面分析
    • 對主要公司進行SWOT分析（最多3家公司）
  • 區域細分
    • 根據客戶的興趣，我們將提供主要國家的市場估算和預測，以及複合年成長率（註：需經可行性確認）。
  • 競爭性標竿分析
    • 根據產品系列、企業發展和策略聯盟對重點公司進行基準分析。

目錄

第1章執行摘要

  • 市場概覽及主要亮點
  • 促進因素、挑戰與機遇
  • 競爭格局概述
  • 戰略洞察與建議

第2章：研究框架

  • 研究目標和範圍
  • 相關人員分析
  • 研究假設和限制
  • 調查方法

第3章 市場動態與趨勢分析

  • 市場定義與結構
  • 主要市場促進因素
  • 市場限制與挑戰
  • 投資成長機會和重點領域
  • 產業威脅與風險評估
  • 技術與創新展望
  • 新興市場/高成長市場
  • 監管和政策環境
  • 新冠疫情的影響及復甦前景

第4章：競爭環境與策略評估

  • 波特五力分析
    • 供應商的議價能力
    • 買方的議價能力
    • 替代品的威脅
    • 新進入者的威脅
    • 競爭公司之間的競爭
  • 主要公司市佔率分析
  • 產品基準評效和效能比較

第5章 全球細胞與基因治療市場：依製造服務分類

  • 細胞療法生產
  • 基因治療生產
  • 病毒載體製造
  • 質體DNA生產
  • 製程開發與最佳化
  • 分析、開發和測試

第6章 全球細胞與基因治療市場：依治療類型分類

  • 自體細胞療法
  • 異體細胞療法
  • 體外基因治療
  • 體內基因治療
  • 基因編輯細胞療法
  • 幹細胞療法
  • 其他細胞和基因療法

第7章 全球細胞與基因治療市場：依載體類型分類

  • 腺結合病毒載體
  • 慢病毒載體
  • 腺病毒載體
  • 逆轉錄病毒載體
  • 單純皰疹病毒載體
  • 非病毒遞送系統
  • 其他向量類型

第8章 全球細胞與基因治療市場：依生產階段分類

  • 臨床前生產
  • 第一階段生產
  • 第二階段生產
  • 第三階段生產
  • 商業生產
  • 製程驗證和規模化
  • 技術轉移

第9章 全球細胞與基因治療市場：依生產流程分類

  • 上游工程
  • 下游加工
  • 細胞採集和獲取
  • 細胞增殖和活化
  • 基因轉移和轉導
  • 細胞收集和製劑
  • 冷凍和儲存

第10章 全球細胞與基因治療市場：依最終用戶分類

  • 製藥公司
  • 生技公司
  • 合約研發生產組織（CDMO）
  • 學術研究機構
  • 醫院和臨床中心
  • 政府和公共研究機構
  • 其他最終用戶

第11章 全球細胞與基因治療市場：按地區分類

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 比利時
    • 瑞典
    • 瑞士
    • 波蘭
    • 其他歐洲國家
  • 亞太地區
    • 中國
    • 日本
    • 印度
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 馬來西亞
    • 新加坡
    • 越南
    • 其他亞太國家
  • 南美洲
    • 巴西
    • 阿根廷
    • 哥倫比亞
    • 智利
    • 秘魯
    • 其他南美國家
  • 世界其他地區（RoW）
    • 中東
      • 沙烏地阿拉伯
      • 阿拉伯聯合大公國
      • 卡達
      • 以色列
      • 其他中東國家
    • 非洲
      • 南非
      • 埃及
      • 摩洛哥
      • 其他非洲國家

第12章 策略市場資訊

  • 工業價值網路和供應鏈評估
  • 空白區域和機會地圖
  • 產品演進與市場生命週期分析
  • 通路、經銷商和打入市場策略的評估

第13章 產業趨勢與策略舉措

  • 併購
  • 夥伴關係、聯盟和合資企業
  • 新產品發布和認證
  • 擴大生產能力和投資
  • 其他策略舉措

第14章：公司簡介

  • Lonza Group AG
  • Charles River Laboratories International, Inc.
  • Catalent, Inc.
  • THERMO FISHER SCIENTIFIC INC.
  • Danaher Corporation
  • Samsung Biologics Co., Ltd.
  • Merck KGaA
  • AGC Inc.
  • Oxford Biomedica plc
  • Sartorius AG
  • Repligen Corporation
  • Recipharm AB
  • Fujifilm Holdings Corporation
  • WuXi AppTec Co., Ltd.
  • WuXi Biologics（Cayman）Inc.
  • GenScript Biotech Corporation
  • Almac Group
  • Orgenesis Inc.
Product Code: SMRC40128

According to Stratistics MRC, the Global Cell & Gene Therapy Manufacturing Market is accounted for $6.0 billion in 2026 and is expected to reach $18.5 billion by 2034 growing at a CAGR of 15.1% during the forecast period. Cell and gene therapy manufacturing refers to the specialized processes and facilities designed to produce living cells and genetic materials for therapeutic applications. They function by isolating, modifying, and expanding patient or donor cells under strict regulatory conditions to ensure safety, efficacy, and consistency. These systems encompass viral vector production, cell culture, and purification technologies that enable the scalable creation of advanced therapies. Their application ensures the reliable delivery of curative treatments for genetic disorders, cancers, and rare diseases, supporting the global expansion of regenerative medicine.

Market Dynamics:

Driver:

Rising Prevalence of Genetic Disorders

The escalating global prevalence of genetic and rare diseases compels pharmaceutical companies to adopt cell and gene therapy manufacturing platforms offering curative treatment alternatives. Growing recognition of the long-term benefits of one-time therapies is accelerating the integration of these advanced manufacturing processes into clinical development frameworks. This transition is supported by advancements in viral vector production, which enhance therapeutic yield. Consequently, biotech firms are investing in specialized manufacturing technologies to achieve compliance with efficacy benchmarks while optimizing production costs.

Restraint:

Complex Regulatory and Quality Control Requirements

The substantial regulatory complexities associated with producing living cell therapies represent a significant barrier to widespread commercial adoption. Developing highly consistent and safe manufacturing processes often requires complex quality control techniques and sophisticated monitoring systems, which escalate overall production costs. Furthermore, the variability in patient-derived starting materials limits the operational reliability of standardized manufacturing pipelines. These factors collectively constrain market expansion, particularly for smaller enterprises with limited regulatory expertise.

Opportunity:

Expansion in Allogeneic Off-the-Shelf Therapies

The allogeneic therapy sector presents substantial growth opportunities for cell and gene therapy manufacturing providers due to increasing demand for scalable, donor-derived treatments. Advanced manufacturing platforms offer a highly effective pathway to produce standardized therapeutic batches without relying on patient-specific cells, utilizing robust cell culture techniques as primary inputs. As global investments in regenerative medicine expand, the adoption of advanced allogeneic manufacturing solutions is expected to surge significantly.

Threat:

Competition from Small Molecule Drugs

The continuous reliance on traditional small molecule drug development poses a considerable threat to the cell and gene therapy manufacturing market. Conventional chemical synthesis and established pharmaceutical production methods often exhibit superior cost-effectiveness under current healthcare budgets and can be more economically viable for treating chronic conditions. Additionally, the rapid advancement of targeted protein degradation technologies is enhancing the efficiency of conventional therapeutic methods. This competitive pressure may hinder market penetration.

Covid-19 Impact:

The pandemic initially disrupted supply chains and delayed clinical trials due to facility closures. However, the subsequent need for rapid vaccine development accelerated the adoption of advanced viral vector manufacturing platforms for therapeutic production. Post-pandemic, the heightened focus on biodefense and regenerative medicine has reinforced long-term investments in cell and gene therapy manufacturing technologies, driving robust market recovery and expansion across diverse pharmaceutical sectors globally.

The cell therapy manufacturing segment is expected to be the largest during the forecast period

The cell therapy manufacturing segment is expected to account for the largest market share during the forecast period, due to its foundational role and widespread applicability across diverse therapeutic environments. Cell therapy manufacturing platforms offer exceptional production scalability and operate effectively in expanding patient-derived cells, which significantly reduces treatment delays and minimizes cellular contamination in daily production processes. As industries increasingly prioritize efficient and cost-effective regenerative medicine methods, the demand for specialized cell therapy manufacturing continues to surge, thereby solidifying its dominant market position.

The gene-edited cell therapy segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the gene-edited cell therapy segment is predicted to witness the highest growth rate, driven by rapid advancements in CRISPR technology and cellular engineering. These technologies enable the precise modification of genetic sequences to produce highly specialized and robust therapeutic outputs tailored for specific disease applications. The ability to enhance editing efficiency, operational scalability, and therapeutic safety through advanced gene-editing integration significantly improves process economics, accelerating commercial adoption globally.

Region with largest share:

During the forecast period, the North America region is expected to hold the largest market share, due to the presence of well-established biotechnology industries and advanced manufacturing infrastructure that heavily utilize cell and gene therapy manufacturing. The region benefits from substantial research and development investments, robust intellectual property protection, and supportive government initiatives promoting technological innovation in healthcare. Furthermore, the early adoption of advanced manufacturing platforms by key industry players in the United States and Canada reinforces the region's dominant position globally.

Region with highest CAGR:

Over the forecast period, the Asia Pacific region is anticipated to exhibit the highest CAGR, due to rapid biotechnology modernization and expanding regenerative medicine sectors in emerging economies. Countries such as China, India, and Japan are increasingly investing in manufacturing infrastructure and cell therapy technologies to meet growing domestic healthcare demands and stringent efficiency regulations. Additionally, favorable government policies, rising foreign direct investment, and the availability of cost-effective technological resources are collectively driving the accelerated adoption of cell and gene therapy manufacturing across the region.

Key players in the market

Some of the key players in Cell & Gene Therapy Manufacturing Market include Lonza Group AG, Charles River Laboratories International, Inc., Catalent, Inc., Thermo Fisher Scientific Inc., Danaher Corporation, Samsung Biologics Co., Ltd., Merck KGaA, AGC Inc., Oxford Biomedica plc, Sartorius AG, Repligen Corporation, Recipharm AB, Fujifilm Holdings Corporation, WuXi AppTec Co., Ltd., WuXi Biologics (Cayman) Inc., GenScript Biotech Corporation, Almac Group, and Orgenesis Inc.

Key Developments:

In September 2026, Lonza Group AG launched a next-generation viral vector manufacturing platform optimized for high-titer production, achieving a thirty percent improvement in yield while significantly reducing contamination risks for global biotech researchers.

In August 2026, Charles River Laboratories International, Inc. expanded its cell therapy capacity through a strategic partnership with a leading academic firm, enabling the scalable deployment of novel quality control modules for regenerative medicine.

In July 2026, Catalent, Inc. secured a major supply agreement to provide customized gene therapy manufacturing services for a prominent pharmaceutical company, facilitating the efficient integration of advanced viral vector tools into next-generation therapeutic ecosystems globally.

Manufacturing Services Covered:

  • Cell Therapy Manufacturing
  • Gene Therapy Manufacturing
  • Viral Vector Manufacturing
  • Plasmid DNA Manufacturing
  • Process Development and Optimization
  • Analytical Development and Testing

Therapy Types Covered:

  • Autologous Cell Therapy
  • Allogeneic Cell Therapy
  • Ex Vivo Gene Therapy
  • In Vivo Gene Therapy
  • Gene-Edited Cell Therapy
  • Stem Cell Therapy
  • Other Cell and Gene Therapies

Vector Types Covered:

  • Adeno-Associated Viral Vectors
  • Lentiviral Vectors
  • Adenoviral Vectors
  • Retroviral Vectors
  • Herpes Simplex Viral Vectors
  • Non-Viral Delivery Systems
  • Other Vector Types

Manufacturing Stages Covered:

  • Preclinical Manufacturing
  • Phase I Manufacturing
  • Phase II Manufacturing
  • Phase III Manufacturing
  • Commercial Manufacturing
  • Process Validation and Scale-Up
  • Technology Transfer

Manufacturing Workflows Covered:

  • Upstream Processing
  • Downstream Processing
  • Cell Collection and Sourcing
  • Cell Expansion and Activation
  • Gene Transfer and Transduction
  • Cell Harvesting and Formulation
  • Cryopreservation and Storage

End Users Covered:

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Contract Development and Manufacturing Organizations
  • Academic and Research Institutes
  • Hospitals and Clinical Centers
  • Government and Public Research Organizations
  • Other End Users

Regions Covered:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • United Kingdom
    • Germany
    • France
    • Italy
    • Spain
    • Netherlands
    • Belgium
    • Sweden
    • Switzerland
    • Poland
    • Rest of Europe
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Indonesia
    • Thailand
    • Malaysia
    • Singapore
    • Vietnam
    • Rest of Asia Pacific
  • South America
    • Brazil
    • Argentina
    • Colombia
    • Chile
    • Peru
    • Rest of South America
  • Rest of the World (RoW)
    • Middle East
  • Saudi Arabia
  • United Arab Emirates
  • Qatar
  • Israel
  • Rest of Middle East
    • Africa
  • South Africa
  • Egypt
  • Morocco
  • Rest of Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2023, 2024, 2025, 2026, 2027, 2028, 2030, 2032 and 2034
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

  • 1.1 Market Snapshot and Key Highlights
  • 1.2 Growth Drivers, Challenges, and Opportunities
  • 1.3 Competitive Landscape Overview
  • 1.4 Strategic Insights and Recommendations

2 Research Framework

  • 2.1 Study Objectives and Scope
  • 2.2 Stakeholder Analysis
  • 2.3 Research Assumptions and Limitations
  • 2.4 Research Methodology
    • 2.4.1 Data Collection (Primary and Secondary)
    • 2.4.2 Data Modeling and Estimation Techniques
    • 2.4.3 Data Validation and Triangulation
    • 2.4.4 Analytical and Forecasting Approach

3 Market Dynamics and Trend Analysis

  • 3.1 Market Definition and Structure
  • 3.2 Key Market Drivers
  • 3.3 Market Restraints and Challenges
  • 3.4 Growth Opportunities and Investment Hotspots
  • 3.5 Industry Threats and Risk Assessment
  • 3.6 Technology and Innovation Landscape
  • 3.7 Emerging and High-Growth Markets
  • 3.8 Regulatory and Policy Environment
  • 3.9 Impact of COVID-19 and Recovery Outlook

4 Competitive and Strategic Assessment

  • 4.1 Porter's Five Forces Analysis
    • 4.1.1 Supplier Bargaining Power
    • 4.1.2 Buyer Bargaining Power
    • 4.1.3 Threat of Substitutes
    • 4.1.4 Threat of New Entrants
    • 4.1.5 Competitive Rivalry
  • 4.2 Market Share Analysis of Key Players
  • 4.3 Product Benchmarking and Performance Comparison

5 Global Cell & Gene Therapy Manufacturing Market, By Manufacturing Service

  • 5.1 Cell Therapy Manufacturing
  • 5.2 Gene Therapy Manufacturing
  • 5.3 Viral Vector Manufacturing
  • 5.4 Plasmid DNA Manufacturing
  • 5.5 Process Development and Optimization
  • 5.6 Analytical Development and Testing

6 Global Cell & Gene Therapy Manufacturing Market, By Therapy Type

  • 6.1 Autologous Cell Therapy
  • 6.2 Allogeneic Cell Therapy
  • 6.3 Ex Vivo Gene Therapy
  • 6.4 In Vivo Gene Therapy
  • 6.5 Gene-Edited Cell Therapy
  • 6.6 Stem Cell Therapy
  • 6.7 Other Cell and Gene Therapies

7 Global Cell & Gene Therapy Manufacturing Market, By Vector Type

  • 7.1 Adeno-Associated Viral Vectors
  • 7.2 Lentiviral Vectors
  • 7.3 Adenoviral Vectors
  • 7.4 Retroviral Vectors
  • 7.5 Herpes Simplex Viral Vectors
  • 7.6 Non-Viral Delivery Systems
  • 7.7 Other Vector Types

8 Global Cell & Gene Therapy Manufacturing Market, By Manufacturing Stage

  • 8.1 Preclinical Manufacturing
  • 8.2 Phase I Manufacturing
  • 8.3 Phase II Manufacturing
  • 8.4 Phase III Manufacturing
  • 8.5 Commercial Manufacturing
  • 8.6 Process Validation and Scale-Up
  • 8.7 Technology Transfer

9 Global Cell & Gene Therapy Manufacturing Market, By Manufacturing Workflow

  • 9.1 Upstream Processing
  • 9.2 Downstream Processing
  • 9.3 Cell Collection and Sourcing
  • 9.4 Cell Expansion and Activation
  • 9.5 Gene Transfer and Transduction
  • 9.6 Cell Harvesting and Formulation
  • 9.7 Cryopreservation and Storage

10 Global Cell & Gene Therapy Manufacturing Market, By End User

  • 10.1 Pharmaceutical Companies
  • 10.2 Biotechnology Companies
  • 10.3 Contract Development and Manufacturing Organizations
  • 10.4 Academic and Research Institutes
  • 10.5 Hospitals and Clinical Centers
  • 10.6 Government and Public Research Organizations
  • 10.7 Other End Users

11 Global Cell & Gene Therapy Manufacturing Market, By Geography

  • 11.1 North America
    • 11.1.1 United States
    • 11.1.2 Canada
    • 11.1.3 Mexico
  • 11.2 Europe
    • 11.2.1 United Kingdom
    • 11.2.2 Germany
    • 11.2.3 France
    • 11.2.4 Italy
    • 11.2.5 Spain
    • 11.2.6 Netherlands
    • 11.2.7 Belgium
    • 11.2.8 Sweden
    • 11.2.9 Switzerland
    • 11.2.10 Poland
    • 11.2.11 Rest of Europe
  • 11.3 Asia Pacific
    • 11.3.1 China
    • 11.3.2 Japan
    • 11.3.3 India
    • 11.3.4 South Korea
    • 11.3.5 Australia
    • 11.3.6 Indonesia
    • 11.3.7 Thailand
    • 11.3.8 Malaysia
    • 11.3.9 Singapore
    • 11.3.10 Vietnam
    • 11.3.11 Rest of Asia Pacific
  • 11.4 South America
    • 11.4.1 Brazil
    • 11.4.2 Argentina
    • 11.4.3 Colombia
    • 11.4.4 Chile
    • 11.4.5 Peru
    • 11.4.6 Rest of South America
  • 11.5 Rest of the World (RoW)
    • 11.5.1 Middle East
      • 11.5.1.1 Saudi Arabia
      • 11.5.1.2 United Arab Emirates
      • 11.5.1.3 Qatar
      • 11.5.1.4 Israel
      • 11.5.1.5 Rest of Middle East
    • 11.5.2 Africa
      • 11.5.2.1 South Africa
      • 11.5.2.2 Egypt
      • 11.5.2.3 Morocco
      • 11.5.2.4 Rest of Africa

12 Strategic Market Intelligence

  • 12.1 Industry Value Network and Supply Chain Assessment
  • 12.2 White-Space and Opportunity Mapping
  • 12.3 Product Evolution and Market Life Cycle Analysis
  • 12.4 Channel, Distributor, and Go-to-Market Assessment

13 Industry Developments and Strategic Initiatives

  • 13.1 Mergers and Acquisitions
  • 13.2 Partnerships, Alliances, and Joint Ventures
  • 13.3 New Product Launches and Certifications
  • 13.4 Capacity Expansion and Investments
  • 13.5 Other Strategic Initiatives

14 Company Profiles

  • 14.1 Lonza Group AG
  • 14.2 Charles River Laboratories International, Inc.
  • 14.3 Catalent, Inc.
  • 14.4 THERMO FISHER SCIENTIFIC INC.
  • 14.5 Danaher Corporation
  • 14.6 Samsung Biologics Co., Ltd.
  • 14.7 Merck KGaA
  • 14.8 AGC Inc.
  • 14.9 Oxford Biomedica plc
  • 14.10 Sartorius AG
  • 14.11 Repligen Corporation
  • 14.12 Recipharm AB
  • 14.13 Fujifilm Holdings Corporation
  • 14.14 WuXi AppTec Co., Ltd.
  • 14.15 WuXi Biologics (Cayman) Inc.
  • 14.16 GenScript Biotech Corporation
  • 14.17 Almac Group
  • 14.18 Orgenesis Inc.

List of Tables

  • Table 1 Global Cell & Gene Therapy Manufacturing Market Outlook, By Region (2023-2034) ($MN)
  • Table 2 Global Cell & Gene Therapy Manufacturing Market Outlook, By Manufacturing Service (2023-2034) ($MN)
  • Table 3 Global Cell & Gene Therapy Manufacturing Market Outlook, By Cell Therapy Manufacturing (2023-2034) ($MN)
  • Table 4 Global Cell & Gene Therapy Manufacturing Market Outlook, By Gene Therapy Manufacturing (2023-2034) ($MN)
  • Table 5 Global Cell & Gene Therapy Manufacturing Market Outlook, By Viral Vector Manufacturing (2023-2034) ($MN)
  • Table 6 Global Cell & Gene Therapy Manufacturing Market Outlook, By Plasmid DNA Manufacturing (2023-2034) ($MN)
  • Table 7 Global Cell & Gene Therapy Manufacturing Market Outlook, By Process Development and Optimization (2023-2034) ($MN)
  • Table 8 Global Cell & Gene Therapy Manufacturing Market Outlook, By Analytical Development and Testing (2023-2034) ($MN)
  • Table 9 Global Cell & Gene Therapy Manufacturing Market Outlook, By Therapy Type (2023-2034) ($MN)
  • Table 10 Global Cell & Gene Therapy Manufacturing Market Outlook, By Autologous Cell Therapy (2023-2034) ($MN)
  • Table 11 Global Cell & Gene Therapy Manufacturing Market Outlook, By Allogeneic Cell Therapy (2023-2034) ($MN)
  • Table 12 Global Cell & Gene Therapy Manufacturing Market Outlook, By Ex Vivo Gene Therapy (2023-2034) ($MN)
  • Table 13 Global Cell & Gene Therapy Manufacturing Market Outlook, By In Vivo Gene Therapy (2023-2034) ($MN)
  • Table 14 Global Cell & Gene Therapy Manufacturing Market Outlook, By Gene-Edited Cell Therapy (2023-2034) ($MN)
  • Table 15 Global Cell & Gene Therapy Manufacturing Market Outlook, By Stem Cell Therapy (2023-2034) ($MN)
  • Table 16 Global Cell & Gene Therapy Manufacturing Market Outlook, By Other Cell and Gene Therapies (2023-2034) ($MN)
  • Table 17 Global Cell & Gene Therapy Manufacturing Market Outlook, By Vector Type (2023-2034) ($MN)
  • Table 18 Global Cell & Gene Therapy Manufacturing Market Outlook, By Adeno-Associated Viral Vectors (2023-2034) ($MN)
  • Table 19 Global Cell & Gene Therapy Manufacturing Market Outlook, By Lentiviral Vectors (2023-2034) ($MN)
  • Table 20 Global Cell & Gene Therapy Manufacturing Market Outlook, By Adenoviral Vectors (2023-2034) ($MN)
  • Table 21 Global Cell & Gene Therapy Manufacturing Market Outlook, By Retroviral Vectors (2023-2034) ($MN)
  • Table 22 Global Cell & Gene Therapy Manufacturing Market Outlook, By Herpes Simplex Viral Vectors (2023-2034) ($MN)
  • Table 23 Global Cell & Gene Therapy Manufacturing Market Outlook, By Non-Viral Delivery Systems (2023-2034) ($MN)
  • Table 24 Global Cell & Gene Therapy Manufacturing Market Outlook, By Other Vector Types (2023-2034) ($MN)
  • Table 25 Global Cell & Gene Therapy Manufacturing Market Outlook, By Manufacturing Stage (2023-2034) ($MN)
  • Table 26 Global Cell & Gene Therapy Manufacturing Market Outlook, By Preclinical Manufacturing (2023-2034) ($MN)
  • Table 27 Global Cell & Gene Therapy Manufacturing Market Outlook, By Phase I Manufacturing (2023-2034) ($MN)
  • Table 28 Global Cell & Gene Therapy Manufacturing Market Outlook, By Phase II Manufacturing (2023-2034) ($MN)
  • Table 29 Global Cell & Gene Therapy Manufacturing Market Outlook, By Phase III Manufacturing (2023-2034) ($MN)
  • Table 30 Global Cell & Gene Therapy Manufacturing Market Outlook, By Commercial Manufacturing (2023-2034) ($MN)
  • Table 31 Global Cell & Gene Therapy Manufacturing Market Outlook, By Process Validation and Scale-Up (2023-2034) ($MN)
  • Table 32 Global Cell & Gene Therapy Manufacturing Market Outlook, By Technology Transfer (2023-2034) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Rest of the World (RoW) Regions are also represented in the same manner as above.